In the fruquintinib plus BSC group versus the placebo plus BSC group, the most frequently reported relevant medical history at study entry included hypertension (preferred term; 49.8% vs 52.2%), infections and infestations (SOC, 14.3% vs 16.5%; including the preferred term urinary tract infection), and investigations (SOC, 10.1% vs 10.4%; including the preferred terms increased AST, ALT, and blood bilirubin) (Supplementary Table S2). Here, GPT is linked to Hypertension.